Other variants, such as TM6SF2 E167K and MBOAT7, are linked to MASLD progression, with TM6SF2 showing a paradoxical protective effect against cardiovascular events despite worsening liver disease [159,160]. This evidence concerns the gene TM6SF2 and liver disorder.